Phase 2 Pulmonary Hypertension Trial, Not Yet Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a type of scarring lung disease (ILD), confirmed by a chest CT scan taken within the last 12 months, showing that at least 10% of your lung tissue is affected by scarring.
- Your lung capacity (how much air your lungs can hold) falls within a specific range — not too low and not too high — as measured by a breathing test called spirometry (confirm with trial site for exact numbers).
- You have had at least ONE of the following recent heart tests showing signs of raised pressure in the lungs: a right heart catheterization procedure within the last 18 months showing specific pressure readings, OR a heart ultrasound (echocardiogram) within the last 18 months showing elevated pressure in the right side of the heart, without significant problems with the left side of the heart.
Who may not be able to join:
- You have been diagnosed with, or are suspected of having, certain other types of pulmonary hypertension (high blood pressure in the lungs) classified under specific medical groups (WHO Groups 1, 2, 4, or 5) (confirm with trial site).
- You have taken certain medications for pulmonary hypertension — such as specific tablets, injections, or infusions — within the last 30 days, or a medication called sotatercept within the last 180 days.
- You have certain other heart or lung conditions alongside your ILD (confirm with trial site for the full list of conditions).
- You are taking medication to treat your scarring lung disease (such as anti-fibrotic, immunosuppressant, or anti-inflammatory drugs) but have not been on a stable, unchanged dose for at least 30 days, or you have started a new lung disease treatment within the last 90 days.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +1 339 337 4053
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Mean Change from Baseline in PVR up to 16 Weeks; Number of Participants with Adverse Events (AEs), Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs); Number of Participants with Clinically Significant Changes from Baseline in Safety Laboratory Assessments, 12-Lead Electrocardiogram (ECG) Assessments and Vital Sign Assessments
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.